Inhibition of Autophagy Enhances the Antitumor Effect of Thioridazine in Acute Lymphoblastic Leukemia Cells.
acute lymphoblastic leukemia
apoptosis
autophagy
thioridazine
viability
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
20 Apr 2021
20 Apr 2021
Historique:
received:
25
02
2021
revised:
15
04
2021
accepted:
16
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Acute lymphoblastic leukemia (ALL) is an aggressive malignant disorder of lymphoid progenitor cells that affects children and adults. Despite the high cure rates, drug resistance still remains a significant clinical problem, which stimulates the development of new therapeutic strategies and drugs to improve the disease outcome. Antipsychotic phenothiazines have emerged as potential candidates to be repositioned as antitumor drugs. It was previously shown that the anti-histaminic phenothiazine derivative promethazine induced autophagy-associated cell death in chronic myeloid leukemia cells, although autophagy can act as a "double-edged sword" contributing to cell survival or cell death. Here we evaluated the role of autophagy in thioridazine (TR)-induced cell death in the human ALL model. TR induced apoptosis in ALL Jurkat cells and it was not cytotoxic to normal peripheral mononuclear blood cells. TR promoted the activation of caspase-8 and -3, which was associated with increased NOXA/MCL-1 ratio and autophagy triggering. AMPK/PI3K/AKT/mTOR and MAPK/ERK pathways are involved in TR-induced cell death. The inhibition of the autophagic process enhanced the cytotoxicity of TR in Jurkat cells, highlighting autophagy as a targetable process for drug development purposes in ALL.
Identifiants
pubmed: 33923896
pii: life11040365
doi: 10.3390/life11040365
pmc: PMC8073363
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2006/00995-5
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2012/12247-8
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2016/07367-5
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2018/25747-5
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : 312020/2019-8
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
ID : 001
Références
Oncogene. 2017 Jul 27;36(30):4267-4276
pubmed: 28346428
Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63
pubmed: 24355989
J Appl Toxicol. 2021 Jan;41(1):82-94
pubmed: 32852120
Immunol Res. 2011 Apr;49(1-3):248-68
pubmed: 21170740
Biomed Pharmacother. 2018 Jul;103:699-707
pubmed: 29680738
Oncotarget. 2017 May 9;8(19):31901-31914
pubmed: 28404874
Oncogene. 2007 May 14;26(22):3227-39
pubmed: 17496918
Toxicology. 2015 Apr 1;330:44-54
pubmed: 25686698
Ann Med. 2006;38(3):200-11
pubmed: 16720434
Can J Psychiatry. 1997 Mar;42(2):152-62
pubmed: 9067064
Nat Biotechnol. 2012 Jul 10;30(7):671-8
pubmed: 22781696
Blood. 2012 Oct 25;120(17):3397-406
pubmed: 22898602
Biochem Pharmacol. 2015 Mar 1;94(1):1-11
pubmed: 25562745
Br J Haematol. 2017 May;177(4):557-561
pubmed: 28295185
Carcinogenesis. 2013 Sep;34(9):2080-9
pubmed: 23689352
Anticancer Res. 2016 Nov;36(11):5701-5706
pubmed: 27793891
Sci Rep. 2016 Jun 09;6:27540
pubmed: 27277973
Oncotarget. 2016 Aug 23;7(34):55690-55703
pubmed: 27494886
Cell Cycle. 2009 Apr 15;8(8):1168-75
pubmed: 19282669
Cancer Manag Res. 2015 Sep 11;7:291-9
pubmed: 26392787
Cell Death Differ. 1999 Jan;6(1):48-54
pubmed: 10200547
Blood Adv. 2020 Sep 22;4(18):4417-4429
pubmed: 32931582
Oncol Lett. 2018 Mar;15(3):2839-2846
pubmed: 29435010
Biochem Pharmacol. 2021 Feb;184:114403
pubmed: 33388284
Cancer Cell. 2006 Jul;10(1):51-64
pubmed: 16843265
Oncogene. 2007 May 14;26(22):3291-310
pubmed: 17496923
Autophagy. 2016;12(1):1-222
pubmed: 26799652
Blood. 2007 Aug 1;110(3):1025-8
pubmed: 17426258
Gynecol Oncol. 2011 Jan;120(1):121-7
pubmed: 21035837
Cancer Chemother Pharmacol. 2004 Mar;53(3):267-75
pubmed: 14663628
Immunity. 2006 Jun;24(6):703-16
pubmed: 16782027
Apoptosis. 2012 Sep;17(9):989-97
pubmed: 22460505
Blood Adv. 2018 Aug 14;2(15):1935-1945
pubmed: 30093531
Lancet. 2008 Mar 22;371(9617):1030-43
pubmed: 18358930
Cancer Cell. 2002 Feb;1(1):75-87
pubmed: 12086890
Biochem Pharmacol. 2014 May 1;89(1):74-85
pubmed: 24607273
Cell Death Dis. 2014 Feb 20;5:e1063
pubmed: 24556678
Nat Rev Mol Cell Biol. 2009 Sep;10(9):623-35
pubmed: 19672277
Nat Cell Biol. 2010 Sep;12(9):814-22
pubmed: 20811353
Anticancer Drugs. 2012 Jul;23(6):614-26
pubmed: 22314265
Clin Cancer Res. 2007 Dec 15;13(24):7271-9
pubmed: 18094407
Acta Pharm Sin B. 2018 Jul;8(4):552-562
pubmed: 30109180
Nat Rev Drug Discov. 2012 Sep;11(9):709-30
pubmed: 22935804
Oncogene. 2003 Dec 8;22(56):8983-98
pubmed: 14663477
Mol Cancer Ther. 2011 Sep;10(9):1533-41
pubmed: 21878654
Nat Rev Clin Oncol. 2011 May 17;8(9):528-39
pubmed: 21587219
Nat Commun. 2020 Aug 18;11(1):4147
pubmed: 32811837
J Toxicol Clin Toxicol. 1995;33(3):199-204
pubmed: 7760442
Nat Rev Mol Cell Biol. 2018 Feb;19(2):121-135
pubmed: 28974774
Oncogene. 2008 Dec;27 Suppl 1:S84-92
pubmed: 19641509
Cell Death Differ. 2018 Jan;25(1):46-55
pubmed: 29053143
Chem Biol Interact. 2020 Jan 5;315:108888
pubmed: 31682805
PLoS One. 2011;6(12):e28491
pubmed: 22164300
Oncotarget. 2016 May 10;7(19):27336-49
pubmed: 27027340
Anticancer Res. 2017 Nov;37(11):5983-5993
pubmed: 29061777
Autophagy. 2016;12(3):515-28
pubmed: 26761524
Autophagy. 2013 Mar;9(3):317-27
pubmed: 23242206
J Clin Invest. 2008 Nov;118(11):3762-74
pubmed: 18830414
Oncogene. 1998 Apr 9;16(14):1803-12
pubmed: 9583678